Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 147

9 diseases · 13 shared-gene connections
9 Diseases
81 Unique genes
0.056 Avg. similarity score
Gallbladder neoplasms Most-connected disease (5 links)
Log in to save this analysis

Save This Analysis

Disease Searched: Primary aldosteronism Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Gallbladder neoplasms 5 5 25
Primary aldosteronism 5 5 16
Peters plus syndrome 4 4 1
Potassium deficiency 4 4 18
Disorder of sex development 3 3 1
Hyperplasia 2 2 31
Conjunctival disease 1 1 2
Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome 1 1 1
neuropathy, hereditary sensory, type 1D 1 1 1

Top shared genes (genes linked to 2+ member diseases)

Gene ⇵ Member diseases ⇵ Linked diseases
B3GLCT 5 / 9 Gallbladder neoplasms, Hyperplasia, Peters plus syndrome, Potassium deficiency and 1 more
RXFP2 5 / 9 Disorder of sex development, Gallbladder neoplasms, Hyperplasia, Potassium deficiency and 1 more
ATL1 2 / 9 neuropathy, hereditary sensory, type 1D, Potassium deficiency
CASZ1 2 / 9 Potassium deficiency, Primary aldosteronism
CCKAR 2 / 9 Gallbladder neoplasms, Primary aldosteronism
DAPK1 2 / 9 Conjunctival disease, Gallbladder neoplasms
LSP1 2 / 9 Potassium deficiency, Primary aldosteronism
NDP 2 / 9 Hyperplasia, Primary aldosteronism
UCHL1 2 / 9 Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome, Gallbladder neoplasms
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Pathways in cancer
DAPK1, DCC, BCL2, EGFR, ERBB2, KEAP1, KRAS, TP53, AKT1, CCND1, HIF1A, HMOX1
 KEGG 23 / 533 6.4× 4.13e-13 8.96e-11 ✓ sig.
Gastric cancer
ABCB1, BCL2, EGFR, ERBB2, KRAS, TP53, AKT1, CCND1, PIK3CA, TCF7L2, TGFB1, FGF5
 KEGG 14 / 150 13.8× 1.08e-12 2.19e-10 ✓ sig.
Prostate cancer
BCL2, EGFR, ERBB2, KRAS, TP53, AKT1, CCND1, MMP9, PIK3CA, TCF7L2, LEF1, INS
 KEGG 12 / 98 18.2× 1.94e-12 3.75e-10 ✓ sig.
Colorectal cancer
DCC, BCL2, EGFR, KRAS, TP53, AKT1, CCND1, PIK3CA, TCF7L2, TGFB1, LEF1
 KEGG 11 / 87 18.7× 1.21e-11 2.03e-9 ✓ sig.
Hepatocellular carcinoma
EGFR, KEAP1, KRAS, TP53, AKT1, CCND1, HMOX1, NFE2L2, PIK3CA, TCF7L2, TGFB1, LEF1
 KEGG 13 / 170 11.3× 9.41e-11 1.30e-8 ✓ sig.
Interleukin-4 and Interleukin-13 signaling
BCL2, TP53, AKT1, CCND1, HIF1A, HMOX1, IL13, MMP9, PTGS2, TGFB1, POMC
 Reactome 11 / 108 15.1× 1.33e-10 1.77e-8 ✓ sig.
Endometrial cancer
EGFR, ERBB2, KRAS, TP53, AKT1, CCND1, PIK3CA, TCF7L2, LEF1
 KEGG 9 / 59 22.6× 1.75e-10 2.27e-8 ✓ sig.
Proteoglycans in cancer
EGFR, ERBB2, ERBB3, ERBB4, KRAS, TP53, AKT1, CCND1, HIF1A, MMP9, PIK3CA, TGFB1
 KEGG 13 / 204 9.4× 9.10e-10 9.83e-8 ✓ sig.
Breast cancer
EGFR, ERBB2, KRAS, TP53, AKT1, CCND1, PIK3CA, TCF7L2, FGF5, LEF1, WNT2B
 KEGG 11 / 148 11.0× 3.97e-9 3.74e-7 ✓ sig.
Bladder cancer
DAPK1, EGFR, ERBB2, KRAS, TP53, CCND1, MMP9
 KEGG 7 / 41 25.3× 9.11e-9 7.79e-7 ✓ sig.
Signaling by ERBB2 KD Mutants
EGFR, ERBB2, ERBB3, ERBB4, KRAS, PIK3CA
 Reactome 6 / 25 35.6× 1.25e-8 1.03e-6 ✓ sig.
Endocrine resistance
BCL2, EGFR, ERBB2, KRAS, TP53, AKT1, CCND1, MMP9, PIK3CA
 KEGG 9 / 99 13.5× 1.94e-8 1.53e-6 ✓ sig.
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
PPP2R5E, EGFR, ERBB2, ERBB3, ERBB4, AKT1, PIK3CA, FGF5, INS
 Reactome 9 / 103 13.0× 2.75e-8 2.08e-6 ✓ sig.
Pancreatic cancer
EGFR, ERBB2, KRAS, TP53, AKT1, CCND1, PIK3CA, TGFB1
 KEGG 8 / 77 15.4× 4.35e-8 3.12e-6 ✓ sig.
PI3K events in ERBB2 signaling
EGFR, ERBB2, ERBB3, ERBB4, PIK3CA
 Reactome 5 / 16 46.3× 5.08e-8 3.59e-6 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
negative regulation of apoptotic process
DAPK1, RXFP2, CAAP1, BCL2, EGFR, ERBB2, ERBB3, ERBB4, TP53, AKT1, HIF1A, HSPB1
 GO:0043066 16 / 524 7.0× 7.28e-10 1.63e-7 ✓ sig.
positive regulation of miRNA transcription
EGFR, TP53, HIF1A, MYCN, TGFB1, AGT, NR3C1
 GO:1902895 7 / 56 28.8× 4.31e-9 7.97e-7 ✓ sig.
positive regulation of epithelial cell proliferation
EGFR, ERBB2, ERBB3, ERBB4, MYCN, TCF7L2, TGFB1
 GO:0050679 7 / 73 22.1× 2.86e-8 4.20e-6 ✓ sig.
positive regulation of gene expression
NWD1, ERBB2, ERBB3, KRAS, TP53, AKT1, HIF1A, IL13, LDLR, MYCN, NFE2L2, TGFB1
 GO:0010628 14 / 504 6.4× 3.14e-8 4.54e-6 ✓ sig.
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
EGFR, ERBB3, ERBB4, LEP, NDP, PIK3CA, TCF7L2, TGFB1, AGT, INS
 GO:0051897 10 / 217 10.6× 3.32e-8 4.76e-6 ✓ sig.
glucose homeostasis
NEUROD1, AKT1, HIF1A, LEP, TCF7L2, FBN2, INS, POMC
 GO:0042593 8 / 134 13.8× 1.17e-7 1.40e-5 ✓ sig.
positive regulation of transcription by RNA polymerase II
NEUROD1, EGFR, TP53, AKT1, BRD4, HIF1A, IL13, KDM1A, MYCN, NDP, NFE2L2, OGG1
 GO:0045944 20 / 1,208 3.8× 1.47e-7 1.70e-5 ✓ sig.
cellular response to hypoxia
BCL2, TP53, HIF1A, NDP, NFE2L2, PTGS2, TGFB1, KCNK3
 GO:0071456 8 / 139 13.3× 1.56e-7 1.78e-5 ✓ sig.
cell population proliferation
BCL2, EGFR, ERBB2, KRAS, TP53, AKT1, CCND1, MYCN, NDP, TGFB1
 GO:0008283 10 / 263 8.8× 2.01e-7 2.21e-5 ✓ sig.
neuron apoptotic process
BCL2, ERBB3, KRAS, TP53, HIF1A, NDP, TGFB1
 GO:0051402 7 / 98 16.5× 2.22e-7 2.41e-5 ✓ sig.
response to oxidative stress
BCL2, KEAP1, TP53, AKT1, HMOX1, NFE2L2, OGG1, PTGS2
 GO:0006979 8 / 146 12.6× 2.28e-7 2.46e-5 ✓ sig.
response to UV-A
EGFR, AKT1, CCND1
 GO:0070141 3 / 4 173× 3.13e-7 3.19e-5 ✓ sig.
epidermal growth factor receptor signaling pathway
EGFR, ERBB2, ERBB3, ERBB4, AKT1, PIK3CA
 GO:0007173 6 / 64 21.6× 3.37e-7 3.39e-5 ✓ sig.
positive regulation of MAPK cascade
EGFR, ERBB2, ERBB3, ERBB4, LEP, TGFB1, FGF5, ADRB2, INS
 GO:0043410 9 / 224 9.3× 5.37e-7 5.02e-5 ✓ sig.
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
AKT1, HSPB1, NFE2L2, INS
 GO:1902176 4 / 18 51.3× 9.57e-7 8.06e-5 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
Potassium deficiency Primary aldosteronism 0.129 4 2.36e-9 2.06e-8 ✓ sig.
Gallbladder neoplasms Primary aldosteronism 0.077 3 2.09e-6 1.16e-5 ✓ sig.
Hyperplasia Primary aldosteronism 0.067 3 4.06e-6 2.15e-5 ✓ sig.
Disorder of sex development Primary aldosteronism 0.059 1 1.04e-3 1.74e-3 ✓ sig.
Peters plus syndrome Primary aldosteronism 0.059 1 1.04e-3 1.74e-3 ✓ sig.
Disorder of sex development Potassium deficiency 0.053 1 1.17e-3 1.89e-3 ✓ sig.
neuropathy, hereditary sensory, type 1D Potassium deficiency 0.053 1 1.17e-3 1.89e-3 ✓ sig.
Peters plus syndrome Potassium deficiency 0.053 1 1.17e-3 1.89e-3 ✓ sig.
Disorder of sex development Gallbladder neoplasms 0.038 1 1.62e-3 2.46e-3 ✓ sig.
Early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome Gallbladder neoplasms 0.038 1 1.62e-3 2.46e-3 ✓ sig.
Gallbladder neoplasms Peters plus syndrome 0.038 1 1.62e-3 2.46e-3 ✓ sig.
Hyperplasia Peters plus syndrome 0.031 1 2.01e-3 2.90e-3 ✓ sig.
Conjunctival disease Gallbladder neoplasms 0.037 1 3.24e-3 4.24e-3 ✓ sig.